Precision medicine in cancer refers to the customization of treatment based on the genetic, molecular, and clinical characteristics of an individual’s tumor. By identifying specific mutations, gene expression profiles, and other biomarkers, clinicians can tailor therapies that target the unique vulnerabilities of each cancer, improving efficacy and minimizing unnecessary toxicity. Precision oncology encompasses a range of technologies, including next-generation sequencing, liquid biopsies, and computational modeling, which help guide therapeutic decisions in real time.

This approach has revolutionized treatment in cancers such as lung, breast, colorectal, and melanoma, where targeted drugs have significantly improved patient outcomes. However, challenges such as tumor heterogeneity, resistance mutations, and accessibility of genomic testing persist. Integrating multi-omic data and real-world evidence is essential for advancing precision strategies beyond individual case studies. The

We actively supports research that contributes to the development and clinical implementation of precision oncology. Submissions that explore novel molecular targets, adaptive trial designs, bioinformatics tools, and disparities in access to personalized care are particularly encouraged. Our goal is to advance precision medicine as a standard of care, enabling more accurate, effective, and equitable cancer treatment.